Also, other potential opportunities for targeted drug development in IBD include specific chemical inhibitors of SK, specific small molecule inhibitors directed against catalytic subunits of the immunoproteasome, and dual inhibitors of the STAT3 and NF-κB signal transduction systems (Figure 2). This evidence concerns the gene STAT3 and inflammatory bowel disease.